Key Takeaways from EUCROF25: AI, Integration, and CRO Challenges in Clinical Trials

Feb 4, 2025 | Article, Past Events

The main topics of discussion at EUCROF25 were the most recent developments in clinical trial technology, specifically automation, artificial intelligence, and system integration.

It became evident that before these technologies can significantly alter clinical trials, fundamental issues with workflow flexibility and system interoperability must be resolved.

What is stopping this vision from becoming reality? Many CROs are still slowed down by inefficiencies, inflexible systems, and integration problems. To move forward, we must first address these fundamental challenges.

Where are CROs struggling?

  • Integration is still a big problem.
    The majority of system providers only enable interoperability within their own ecosystem, despite the fact that many make claims about seamless integration. Sponsors and CROs are left to navigate complex and fragmented workflows.
  • Rigid, non-modular systems limit adaptability.
    Technology should support experts, not replace them. Automation should streamline processes while keeping human expertise at the core, ensuring clinical professionals can make better, faster, and more informed decisions. Many EDC systems and clinical trial platforms have rigid workflows that cannot handle the complexity of contemporary trials. There is a greater need than ever for patient-centered, modular, and adaptable solutions.
  • Decentralized trials and patient recruitment need better support.
    As the industry shifts toward decentralized trials and home nursing, existing systems are struggling to keep up. Faster recruitment in decentralized trial models requires better system integration to fully support these complex study types.
  • Compliance and data management pressures are growing.
    With evolving regulatory requirements, CROs must ensure data accuracy, compliance, and efficiency. Many current systems lack the agility needed to support these increasing demands.

The market demands real solutions – not partial fixes

The discussions at EUCROF25 made one thing clear: CROs are not just looking for better tools, they play a crucial role in delivering successful trials and need technology that truly supports their work. The industry must shift toward greater flexibility, interoperability, and efficiency to empower CROs to overcome operational challenges and move toward progress.

Attendees emphasized that:

  • Integration should mean full connectivity, not just partial interoperability within a closed system.
  • Vendor ecosystems create silos, making true data flow across platforms nearly impossible.
  • Technology should remove complexity, not add more manual workarounds.

Rather than more of the same, the market is calling for smarter, adaptable, and truly interconnected systems that solve, not prolong, these persistent challenges.

Final Thoughts

EUCROF25 reinforced what many in the industry already suspected: while we are moving forward, some obstacles remain. AI, automation, and software innovations are exciting, but if CROs are still struggling with outdated processes and rigid systems, is true progress being made?

Are we truly progressing toward a unified, patient-centric clinical trial ecosystem, or are we getting caught up in the promise of innovation without addressing the practical challenges?

Facing similar challenges? Have we missed an important pain point? Let us exchange insights and brainstorm together, because solving these foundational issues is key to opening the full potential of future advancements.

Learn More

Don’t miss any more blog articles and always stay up to date.

By clicking the 'submit' button, you agree to receive regular information via email from Wemedoo AG. You can unsubscribe at any time. You consent to the processing of your personal data for the purpose of sending and analyzing informational emails, as described in our Privacy Policy. You can revoke your consent at any time by sending an informal email to [email protected], with effect for the future. We, Wemedoo AG, use the data you provide solely for the purpose of sending information and only share it with our email marketing service provider.